Cushionflor by Congoleum Corporation

Product Description

Cushionflor was a resilient sheet flooring product manufactured by Congoleum Corporation between approximately 1978 and 1980. Designed as a cushioned vinyl floor covering, the product was marketed and distributed for use in residential and commercial settings where durability and ease of installation were priorities. Congoleum Corporation, headquartered in New Jersey, was one of the dominant American manufacturers of resilient flooring products throughout the mid-to-late twentieth century, producing a wide range of vinyl sheet goods and tile under multiple brand names.

Cushionflor represented a specific product line within Congoleum’s broader flooring catalog, distinguished by its layered, cushioned construction intended to provide underfoot comfort and noise reduction. Sheet flooring of this type was typically manufactured in wide rolls and installed by cutting to fit the dimensions of a room or workspace, often adhered directly to a subfloor using compatible adhesive compounds. The product was sold through flooring distributors, building supply retailers, and contractors serving both new construction and renovation markets during the late 1970s.

Congoleum Corporation has been the subject of substantial asbestos litigation stemming from its flooring product lines, and the company filed for Chapter 11 bankruptcy protection in 2003, citing asbestos liability as a central factor. Despite the bankruptcy proceeding, no dedicated asbestos trust fund was established for Cushionflor specifically, meaning that legal claims related to this product proceed through active litigation rather than a trust fund claims process.

Asbestos Content

Cushionflor is documented as containing chrysotile asbestos during its production years of 1978 through 1980. Chrysotile, also known as white asbestos, is the most commercially prevalent form of asbestos and belongs to the serpentine mineral group. It was widely incorporated into resilient flooring products throughout the twentieth century because of its properties as a reinforcing fiber: chrysotile improved the tensile strength and dimensional stability of vinyl sheet goods, helped regulate thermal expansion, and enhanced resistance to wear and chemical exposure.

In sheet flooring construction of this era, asbestos fibers were typically integrated into one or more layers of the product’s composite structure. These layers could include a backing material, a felt or foam cushioning layer, or a vinyl wear layer, depending on the specific manufacturing process employed. The asbestos content in such products was generally encapsulated within the vinyl or felt matrix during normal, undisturbed use, meaning the fibers were not readily released under ordinary floor traffic conditions. However, the bonded and encapsulated state of the asbestos did not eliminate exposure risk during all phases of the product’s lifecycle, particularly during installation, cutting, sanding, or removal.

The use of chrysotile asbestos in resilient flooring was a well-established industry practice during the period Cushionflor was produced. Regulatory attention to asbestos-containing floor coverings increased significantly during the late 1970s and into the 1980s, with agencies including the Environmental Protection Agency and OSHA issuing guidance and rules addressing asbestos hazards in building materials. The Asbestos Hazard Emergency Response Act (AHERA), enacted in 1986, subsequently codified requirements for identifying and managing asbestos-containing building materials, categories that encompassed resilient sheet flooring products such as Cushionflor.

How Workers Were Exposed

Exposure to chrysotile asbestos from Cushionflor was most directly associated with industrial workers and tradespeople involved in the handling, installation, and removal of the product. Litigation records document that workers encountered the product in a variety of occupational contexts during and after its production window.

During installation, workers cut Cushionflor sheet flooring to size using utility knives, scissors, or other cutting tools. Cutting through the composite layers of the product had the potential to disturb the asbestos-containing matrix and release chrysotile fibers into the immediate work environment. Workers operating in enclosed spaces with limited ventilation — conditions common on construction sites, in commercial interiors, and in industrial facilities — faced a heightened risk of inhaling airborne fibers generated during these tasks.

Removal of existing flooring presented a comparable or greater risk of fiber release. As sheet flooring aged, the adhesive bonds holding it to the subfloor could degrade, and removal often involved scraping, prying, or abrading the material. These mechanical actions were capable of fracturing and powdering the asbestos-containing backing and cushioning layers, generating dust containing respirable chrysotile fibers. Plaintiffs alleged in litigation that workers engaged in flooring demolition and renovation work experienced significant asbestos exposure through these removal activities, particularly in cases where the flooring had not been identified as asbestos-containing prior to disturbance.

Industrial workers generally, including maintenance personnel and facilities workers responsible for upkeep in factories, warehouses, and other commercial environments where Cushionflor may have been installed, were also identified as an exposed population. Routine maintenance tasks such as buffing, sanding, or refinishing floors could disturb the product’s surface and subsurface layers, and workers performing these tasks without appropriate respiratory protection may have been exposed to asbestos fibers over the course of their employment.

The latency period associated with asbestos-related disease — which commonly spans twenty to fifty years between initial exposure and the onset of illness — means that individuals exposed to Cushionflor during its production and installation window of 1978 to 1980 may only now be developing or receiving diagnoses of asbestos-related conditions. Diseases associated with chrysotile asbestos exposure include mesothelioma, asbestosis, lung cancer, and other pulmonary conditions.

Documented Trust Fund / Legal Options

No dedicated asbestos trust fund exists for Cushionflor or for Congoleum Corporation claims arising from this specific product. Although Congoleum filed for Chapter 11 bankruptcy protection in 2003, the company’s bankruptcy reorganization did not result in the establishment of a Section 524(g) asbestos trust fund in the same manner as some other asbestos defendants. Individuals seeking compensation for injuries related to Cushionflor exposure are therefore directed to pursue claims through the civil litigation system rather than through a trust fund claims process.

Litigation records document that plaintiffs have brought claims against Congoleum Corporation and related parties alleging that the company knew or should have known of the hazards associated with asbestos-containing flooring products and failed to adequately warn workers and end users of those risks. Plaintiffs alleged causes of action including negligence, failure to warn, strict products liability, and in some instances fraud or concealment related to the suppression of asbestos hazard information.

Individuals who were employed as flooring installers, industrial maintenance workers, demolition laborers, or in other trades that involved contact with Cushionflor between 1978 and 1980, and who have subsequently received a diagnosis of mesothelioma, asbestosis, lung cancer, or a related asbestos disease, may have grounds for legal action. Because the legal options in Tier 2 litigation cases are product- and jurisdiction-specific, affected individuals are strongly encouraged to consult with an attorney experienced in asbestos litigation to evaluate the viability and appropriate venue for any potential claim. Statutes of limitations governing asbestos personal injury and wrongful death claims vary by state and typically begin running from the date of diagnosis or the date on which the claimant reasonably should have known of the connection between their illness and asbestos exposure.